Next Article in Journal
Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery—Are We There Yet?
Previous Article in Journal
Is Pelvic Plexus Block Superior to Periprostatic Nerve Block for Pain Control during Transrectal Ultrasonography-Guided Prostate Biopsy? A Double-Blind, Randomized Controlled Trial
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer

1
ICON plc, 111 64 Stockholm, Sweden
2
Merck & Co., Inc., North Wales, PA 19454, USA
3
ICON plc, London W12 0BZ, UK
4
ICON plc, 690 03 Lyon, France
5
ICON plc, Boston, MA 02110, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(4), 558; https://doi.org/10.3390/jcm8040558
Received: 18 March 2019 / Revised: 16 April 2019 / Accepted: 19 April 2019 / Published: 24 April 2019
(This article belongs to the Section Oncology)
  |  
PDF [669 KB, uploaded 26 April 2019]
  |  

Abstract

The study objective was to assess US physicians’ Mismatch Repair/Microsatellite Instability (MMR/MSI) testing practices for metastatic colorectal cancer (mCRC) patients. A non-interventional, cross-sectional online survey was conducted among 151 physicians (91 oncologists, 15 surgeons and 45 pathologists) treating mCRC patients in the US. Eligible physicians were US-based with at least 5 years of experience treating CRC patients, had at least one mCRC patient in their routine care in the past 6 months, and had ordered at least one MMR/MSI test for CRC in the past 6 months. Descriptive and logistic regression analyses were performed. Awareness of specific MMR/MSI testing guidelines was high (n = 127, 84.1%). Of those, 93.7% (119/127) physicians had awareness of specific published guidelines with majority 67.2% (80/119) being aware of National Comprehensive Cancer Network (NCCN) guidelines. Universal testing for all CRC patients was performed by 68.9% (104/151) physicians, while 29.8% (45/151) selectively order the test for some CRC patients. Key barriers for testing included insufficient tissue sample (48.3%, 73/151), patient declined to have the test done (35.8%, 54/151) and insurance cost concerns for patients (31.1%, 47/151), while 27.2% (41/151) reported no barriers. The survey demonstrated high awareness and compliance with MMR/MSI testing guidelines although universal testing rates seem to be suboptimal. View Full-Text
Keywords: colorectal cancer; survey; mismatch repair/microsatellite instability testing colorectal cancer; survey; mismatch repair/microsatellite instability testing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Eriksson, J.; Amonkar, M.; Al-Jassar, G.; Lambert, J.; Malmenäs, M.; Chase, M.; Sun, L.; Kollmar, L.; Vichnin, M. Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer. J. Clin. Med. 2019, 8, 558.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top